Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers

JAMA Intern Med. 2019 Dec 1;179(12):1712-1714. doi: 10.1001/jamainternmed.2019.3107.

Abstract

This economic evaluation study estimates the potential Medicare savings from generic substitution and therapeutic interchange of brand-name hypertension medications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin Receptor Antagonists / economics
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / economics
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Antihypertensive Agents / economics
  • Antihypertensive Agents / therapeutic use*
  • Cost Savings
  • Drug Substitution / economics*
  • Drugs, Generic / economics
  • Drugs, Generic / therapeutic use*
  • Humans
  • Hypertension / drug therapy*
  • Medicare
  • United States

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Drugs, Generic